Do Not Sell My Information. Investors Are Buying The Dip In LGI Homes Stock, Forget Tesla, Ford Motor May be the Best Auto Play, Lowe's Has a Winning Quarter But Urges a Familiar Caution, Lumen Technologies.Stock is Steady Turnaround Play, Here’s How To Trade Intuit Stock Post Earnings, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, Receive Analysts' Upgrades and Downgrades Daily. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. But the stock remains in small-cap territory, meaning it has plenty of room for growth. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. But the company has advanced its vaccine candidate into human trials. New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models. Adria Cimino grew up with her nose in a book and a love of storytelling. 2 Wall Street analysts have issued ratings and price targets for Vaxart in the last 12 months. The company doesn't yet have commercialized products. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Read more here about the next great pet stock! The firm has a fifty day moving average price of $7.84 and a 200-day moving average price of $7.42. The government didn't fund Vaxart's program -- at least not so far. We’re motley! The lighter blue line represents the stock's consensus price target. In November, the company said it had completed enrollment. 2 Wall Street analysts have issued ratings and price targets for Vaxart in the last 12 months. See what's happening in the market right now with MarketBeat's real-time news feed. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Shares rose as the company announced its development of the vaccine and investors hoped it might be included in a list of vaccine developers to receive government funding. And it could most certainly happen again. … Cumulative Growth of a $10,000 Investment in Stock Advisor, Did You Miss Out on a 2,000% Gain with Vaxart Stock? Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Today, you can download 7 Best Stocks for the Next 30 Days. Learn everything you need to know about successful options trading with this three-part video course. Export data to Excel for your own analysis. And if Vaxart's program makes it to regulatory authorization, the stock could skyrocket. Want the latest recommendations from Zacks Investment Research? Please log in to your account or sign up in order to add this asset to your watchlist. To see all exchange delays and terms of use please see disclaimer. The stock has a market cap of $990.69 million, a PE ratio of -15.34 and a beta of -0.11. The high price target for VXRT is $22.00 and the low price target for VXRT is $17.00. So any good news ahead can easily send the share price higher. Market data powered by FactSet and Web Financial Group. At the time, the biotech said it expected initial data readouts "in a few weeks." So cautious investors are better off watching this stock market mover from the sidelines. But don't chase Vaxart gains unless you're an aggressive investor. Learn about financial terms, types of investments, trading strategies and more. Their average twelve-month price target is $19.50, predicting that the stock has a possible upside of 161.39%. Vaxart launched the phase 1 trial of its vaccine candidate in October. @themotleyfool #stocks $VXRT, Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart, Copyright, Trademark and Patent Information. Midway through trading Wednesday, the Dow traded down 0.04% to 30,674.36 while the NASDAQ rose 0.25% to 13,646.18. Learn more. Get daily stock ideas top-performing Wall Street analysts. Like more than 50 other companies, Vaxart is developing a potential coronavirus vaccine. Identify stocks that meet your criteria using seven unique stock screeners. Receive a free world-class investing education from MarketBeat. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy.". When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter. View which stocks are hot on social media with MarketBeat's trending stocks report. Stock Advisor launched in February of 2002. In recent trading, shares of Vaxart Inc (Symbol: VXRT) have crossed above the average analyst 12-month target price of $17.67, changing hands for $23.33/share… Click to get this free report VAXART, INC. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Fundamental company data provided by Zacks Investment Research. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Investors have awarded Vaxart (NASDAQ:VXRT) for its innovation this year. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 © American Consumer News, LLC dba MarketBeat® 2010-2021. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Vaxart has a 1 year low of $1.00 and a 1 year high of $24.90. Looking for new stock ideas? Start Your Risk-Free Trial Subscription Here, Buffett's right-hand man says US stock market is overvalued, GameStop shares double after tumbling for much of February, Lawsuits filed against auto insurers over rates in pandemic, Closing prices for crude oil, gold and other commodities, The Latest: China ponders approving 2 more COVID-19 vaccines, ExxonMobil selling some assets for more than $1B, GOP rallies solidly against Democrats' virus relief package, Why McDonald’s Stock is Appetizing at Current Levels, Denison Mines Stock a Uranium Assets Play. But let’s not forget… it wasn’t so long ago that cryptos were dropping by 90% (or more) in just a few weeks time... The figure suggests upside potential of 79% in the year ahead. If the upcoming results are positive, I would expect further share gains. Vaxart is a biotech company that is looking to develop a unique Covid-19 vaccine that can be administered via tablets, eliminating the need for a needle-based injection. Their average twelve-month price target is $19.50, predicting that the stock has a possible upside of 165.67%. The chart below shows how a company's share price and consensus price target have changed over time. Vaxart launched the phase 1 trial of its vaccine candidate in October. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. An article published in Nature Medicine reports data from a … And we do expect news in the near future. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Should You Invest in AIM ImmunoTech Stock For the Long Haul? MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Returns as of 02/25/2021. 02/20 Is bitcoin headed to $100,000 in 2021 or is its price ... Royalty Pharma increases quarterly dividend by 13% to 17 cents a share. But its vaccine doesn't involve a jab; it's a tablet to be taken orally. Vaxart, Inc (US:VXRT) has 270 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. The volatility of Vaxart Inc's share price is greater than that of 89.68% US stocks with at least 200 days of trading history. Want to see which stocks are moving? The dark blue line represents the company's actual price. Don't miss this opportunity as FRPT is already trading over 100 dollars per share!document.write(''); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. Vaxart's market value has climbed from about $16 million at the start of the year to more than $800 million. And we do expect news in the near future. View our full suite of financial calendars and market data tables, all for free. You may have missed out on Vaxart's 2,105% gain this year if you didn't invest in the shares in the first quarter. All rights reserved. Get short term trading ideas from the MarketBeat Idea Engine. O ver the past week, investors optimistically pushed Vaxart’s share price up by over 100%.High short-interest and anticipation of positive Phase 1 results from the … Are you looking for the next great pet stock play? Vaxart Company Profile That's huge progress in a short time. So any good news ahead can easily send the share price higher. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The high price target for VXRT is $22.00 and the low price target for VXRT is $17.00. The S&P also rose, gaining 0.24% to … Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. You can opt out at any time. Don't miss this opportunity as FRPT is already trading over 100 dollars per share! And all of its programs are in phase 2 studies or earlier. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. But if its investigational vaccine is successful, there may be more share performance like that on the horizon. Vaxart, therefore, scores a Strong Buy consensus rating alongside an average analyst price target of $17.67. VXRT's SEC filings can be seen here. Learn more. Stocks with similar financial metrics, market capitalization, and price volatility to Vaxart Inc are KIN, CERS, EPZM, EXK, and UTHR. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Hackensack Nj Police Blotter, Chattanooga Fc Tryouts 2021, Army War College Academic Calendar, Puerto Rican Salsa Artists, Becoming Mrs Lewis Amazon, Surfmist Paint Bunnings, Meijer Computer Training,